Company
Overview
For Investors
News
Team
Executive Board
Management Team
Scientific Advisory Board
Pertussis
Whooping Cough
B. pertussis
Bacteria
Treatment vs Prevention
Subclinical Colonization + Transmission
Adult/adolescent Boosters
Our Science
BPZE1 Vaccine
Why a Live Vaccine?
Preventing Colonization + Transmission
Preclinical Safety
BPZE1 Publications
Disease Science
- Alzheimer’s Disease
- Allergic Disease
- Autoimmune Disease
Clinical
Opportunity
Market
Pipeline
Intellectual Property
B-Tech
Targeting Disease
with
B-Tech
B-Tech
Vector Platform
Vaccine Candidates
B. Pertussis
Disease Research
BioLyo Tech
Contact
Our Science
BPZE1 Vaccine
Why a Live Vaccine?
Preventing Colonization + Transmission
Preclinical Safety
BPZE1 Publications
Disease Science
- Alzheimer’s Disease
- Allergic Disease
- Autoimmune Disease
Join Our Mailing List
BPZE1 Publications
Title
• BPZE1, an intranasal live attenuated pertussis vaccine, evaluated in a Bordetella pertussis challenge study in healthy adults: a phase 2b, randomized, placebo-controlled study. World Vaccine Congress Europe, Barcelona, Spain, October 18, 2023
• Live attenuated Bordetella pertussis intranasal vaccine (BPZE1). World Vaccine Congress, April 6, 2023
• Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanus–diphtheria–acellular pertussis vaccine: a randomised, double-blind, phase 2b trial
• Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study
• Live attenuated pertussis vaccine BPZE1 induces a broad antibody response in humans
• Livening up pertussis vaccine development
• IL-17-dependent SIgA-mediated protection against nasal
Bordetella pertussis
infection by live attenuated BPZE1 vaccine
• A Phase I Clinical Study of a Live Attenuated
Bordetella Pertussis
Vaccine - BPZE1; A Single Centre, Double-Blind, Placebo-Controlled, Dose-Escalating Study of BPZE1 Given Intranasally to Healthy Adult Male Volunteers
• B-cell responses after intranasal vaccination with the novel attenuated
Bordetella Pertussis
vaccine strain BPZE1 in a randomized phase I clinical trial
• Live Attenuated Pertussis Vaccine BPZE1 Protects Baboons Against
Bordetella Pertussis
Disease and Infection
• Heterologous prime-boost immunization with live attenuated
B. pertussis
BPZE1 followed by acellular pertussis vaccine in mice
• New pertussis vaccination approaches: en route to protect newborns?
• Pertussis: acellular, whole-cell, new vaccines, what to choose?
• Live attenuated vaccines against pertussis
• Dose response of attenuated
Bordetella Pertussis
BPZE1-induced protection in mice
• Live Attenuated
B. pertussis
as a Single-Dose Nasal Vaccine against Whooping Cough.
• Highly Attenuated
Bordetella Pertussis
Strain BPZE1 as a Potential Live Vehicle for Delivery of Heterologous Vaccine Candidates
• A Live Attenuated
Bordetella Pertussis
Candidate Vaccine Does Not Cause Disseminating Infection in Gamma Interferon Receptor Knockout Mice
• T- and B-Cell-Mediated Protection Induced by Novel, Live Attenuated Pertussis Vaccine in Mice. Cross Protection against Parapertussis
• Dual mechanism of protection by live attenuated
Bordetella Pertussis
BPZE1 against Bordetella bronchiseptica in mice
• Attenuated
Bordetella Pertussis
BPZE1 protects against allergic airway inflammation and contact dermatitis in mouse models
• Immunogenicity of Live Attenuated
B. pertussis
BPZE1 Producing the Universal Influenza Vaccine Candidate M2e
• Attenuated
Bordetella Pertussis
vaccine protects against respiratory syncytial virus disease via an IL-17-dependent mechanism
• A live, attenuated
Bordetella Pertussis
vaccine provides long-term protection against virulent challenge in a murine model
• Genetic stability of the live attenuated
Bordetella Pertussis
vaccine candidate BPZE1
• Attenuated
Bordetella Pertussis
Vaccine Candidate BPZE1 Promotes Human Dendritic Cell CCL21-Induced Migration and Drives a Th1/Th17 Response
• Long-term immunity against pertussis induced by a single nasal administration of live attenuated
B. pertussis
BPZE1
• Attenuated
Bordetella Pertussis
vaccine strain BPZE1 modulates allergen-induced immunity and prevents allergic pulmonary pathology in a murine model
• Attenuated
Bordetella Pertussis
BPZE1 as a live vehicle for heterologous vaccine antigens delivery through the nasal route
• Possible Options for New Pertussis Vaccines
• Live Attenuated
B. pertussis
BPZE1 Rescues the Immune Functions of Respiratory Syncytial Virus Infected Human Dendritic Cells by Promoting Th1/Th17 Responses
Copyright 2013-2024 ILiAD Biotechnologies